Hyperlipemia therapeutic agent

Details Hyperlipemia therapeutic agent Hyperlipemia therapeutic agent

2006-04-04

2006-04-04

Henley, III, Raymond J. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S549000, C514S560000

Reexamination Certificate

active

07022713

ABSTRACT:
The present invention relates to a hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid or an ester derivative thereof as effective ingredients.According to the present invention, a type IIb and type IV hyperlipemia therapeutic agent having an excellent effect of lowering the cholesterol and triglyceride in blood is provided.

REFERENCES:
patent: 5856336 (1999-01-01), Fujikawa et al.
patent: 6777552 (2004-08-01), Niddam-Hildesheim et al.
patent: 2002/0016312 (2002-02-01), Seed et al.
patent: 2003/0105028 (2003-06-01), Ghosal et al.
McKenney, “New Cholesterol Guidelines, New Treatment Challenges”, Pharmacotherapy, (Jul. 2002), 22(7), 853-63 (Abstract Only, Medline Accession No. 2002380154).
Kiyoshi Mizuguchi, et al., “Ethyl all-cis-5,8,11,14,17-icosapentaenoate modifies the biochemical properties of rat very low-density lipoprotein,” European Journal of Pharmacology, 235 (1993), pp. 221-227.
Kiyoshi Mizuguchi, et al., “The effect of eicosapentaenoic acid ethyl ester (EPA-E) on the metabolism of triglyceride,” J. Jpn. Atheroscier. Soc., 18(5), 1990, pp. 536-537, with English translation.
N. Nakamura, et al., “Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia,” Int J Clin Lab Res (1999) 29, pp. 22-25.
Kiyoshi Mizuguchi, et al., “Mechanism of the lipid-lowering effect of ethyl all-cis-5,8,11,14,17-icosapentaenoate,” European Journal of Pharmacology, 231 (1993), pp. 121-127.
Norio Nakamura, et al., “HMG-CoA Reductase Inhibitors and the Metabolism of Polyunsaturated Fatty Acids-Joint Effects of Eicosapentaenoic Acid and HMG-CoA Reductase Inhibitors”, Progress in Medicine, vol. 19, No. 8, Aug., 1999, pp. 105-111.
Suzuki et al, Atheroscierosis 146 (1999) pp. 259-270.
Aoki et al, Arzneim.-Forsch./Drug Res. 47 (II), 8, (1997) pp. 904-909.

Affiliated with

Also associated with

Rating

Hyperlipemia therapeutic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hyperlipemia therapeutic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hyperlipemia therapeutic agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3551435